Abcellera Biologics Inc
$ 3.99
2.05%
21 Apr - close price
- Market Cap 1,185,357,000 USD
- Current Price $ 3.99
- High / Low $ 4.00 / 3.83
- Stock P/E N/A
- Book Value 3.22
- EPS -0.49
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -0.14 %
- 52 Week High 6.51
- 52 Week Low 1.94
About
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$9.43
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-06 | 2025-08-07 | 2025-05-05 | 2025-02-18 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.03 | -0.19 | -0.12 | -0.15 | -0.12 | -0.17 | -0.13 | -0.14 | -0.17 | -0.1 | -0.11 | -0.14 |
| Estimated EPS | -0.144 | -0.14 | -0.14 | -0.17 | -0.1471 | -0.15 | -0.14 | -0.17 | -0.13 | -0.13 | -0.13 | -0.14 |
| Surprise | 0.114 | -0.05 | 0.02 | 0.02 | 0.0271 | -0.02 | 0.01 | 0.03 | -0.04 | 0.03 | 0.02 | 0 |
| Surprise Percentage | 79.1667% | -35.7143% | 14.2857% | 11.7647% | 18.4228% | -13.3333% | 7.1429% | 17.6471% | -30.7692% | 23.0769% | 15.3846% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.22 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABCL
2026-04-21 05:09:54
AbCellera announced it will present interim Phase 1 clinical data for its antibody therapeutic, ABCL635, during its upcoming first quarter 2026 earnings call on May 11, 2026. ABCL635 is designed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms associated with menopause. The data will include the observed safety profile, pharmacokinetic data, and pharmacodynamic target engagement, with Phase 2 results expected in Q3 2026.
2026-04-20 21:09:54
JonesResearch has initiated coverage of AbCellera Biologics Inc. (ABCL) with a "Buy" rating and an $11 price target, citing the company's validated antibody discovery platform and collaboration with Eli Lilly. AbCellera Biologics reported $75.1 million in revenue and a net loss of $146.4 million for the full year 2025, ending the year with $700 million in liquidity. The company focuses on developing antibody medicines across various therapeutic areas.
2026-04-20 17:29:00
JonesResearch has initiated coverage of AbCellera Biologics Inc. (NASDAQ: ABCL) with a "Buy" rating and an $11 price target, highlighting the company's validated antibody discovery platform and its collaboration with Eli Lilly. AbCellera Biologics, which pivoted to a clinical-stage biotech company in 2025, ended the year with approximately $700 million in liquidity, $75.1 million in revenue, and a reduced net loss. The company specializes in developing antibody medicines for various therapeutic areas by integrating data science, technology, and interdisciplinary expertise.
2026-04-20 17:09:03
AbCellera (Nasdaq: ABCL) will disclose interim Phase 1 clinical data for its ABCL635 therapeutic during its first quarter 2026 earnings call on May 11, 2026. This data will include safety profile, pharmacokinetic, and pharmacodynamic target engagement results for ABCL635, an antibody targeting the neurokinin 3 receptor for treating moderate-to-severe vasomotor symptoms associated with menopause. ABCL635 is currently in a Phase 1/2 study, with Phase 2 results anticipated in Q3 2026.
2026-04-20 14:09:54
Leerink Partners has downgraded AbCellera Biologics (ABCL) in a recent analyst rating. This indicates a revised outlook from the firm regarding the biotech company's stock performance or operational prospects. The specific reasons for the downgrade were not detailed in this snippet.
2026-04-20 14:09:03
AbCellera Biologics Inc. (NASDAQ:ABCL) is scheduled to release interim Phase 1 results for its menopause drug, ABCL635, during its Q1 2026 earnings call on May 11, 2026. The company will share safety, pharmacokinetic, and pharmacodynamic data for ABCL635, an antibody targeting the neurokinin 3 receptor for vasomotor symptoms associated with menopause. Truist Securities has reiterated a Buy rating on AbCellera, citing the upcoming data as a pivotal moment for the company, whose stock has surged 65.7% over the past year.
